Clinical trials
catalyst calendar across sponsors →Studies where TSHA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 observational
Held by 12 tracked-famous managers (D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Squarepoint Ops LLC, Holocene Advisors, LP, +7 more) · FINRA short interest 19.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)NCT05606614Part A: Safety and Tolerability of TSHA-102Non-randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Genetic: TSHA-102 | Rett Syndrome | 17 | Jun 2031 | ≤ 1,776 d | 2026-07-07 |
| Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett SyndromeNCT07480564Primary SafetyOpen-label · Treatment | Phase 3 | Active, not recruiting | Genetic: TSHA-102 | Rett Syndrome | 4 | Jun 2031 | ≤ 1,776 d | 2026-08-19 |
| Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)NCT06152237Primary SafetyRandomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: TSHA-102 | Rett Syndrome | 6 | 2028-11-02 | in 806 d | 2025-10-15 |
| A Study of the Natural Course of SURF1 DeficiencyNCT05277363observationalChange from baseline in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) | — | Withdrawnsponsor's stated reason: The study stopped early, before enrolling its first participant | Other: None (Observational study) | Leigh Syndrome | 0 | 2022-05-04actual | — | 2022-05-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19